



## REFERENCES

1. ATLAS: Study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus long-acting rilpivirine from current antiretroviral regimen in virologically suppressed HIV-1-infected adults <https://clinicaltrials.gov/ct2/show/NCT02951052?term=ATLAS&cond=HIV&rank=3>
2. ATLAS-2M: Efficacy, safety and tolerability study of long-acting cabotegravir plus long-acting rilpivirine (CAB LA + RPV LA) in human-immunodeficiency virus-1 (HIV-1) infected adults. <https://clinicaltrials.gov/ct2/show/NCT03299049?term=ATLAS-2M&rank=1>
3. Black S, Zulliger R, Marcus R, Mark D, Myer L, Bekker LG. Acceptability and challenges of rapid ART initiation among pregnant women in a pilot programme, Cape Town, South Africa. *AIDS Care*. 2014;26(6):736–741.
4. British HIV Association (BHIVA), British Association of Sexual Health and HIV, British Infection Society. UK National Guidelines for HIV Testing 2008. [www.bhiva.org](http://www.bhiva.org) 2008.
5. Bukowski LA, Chandler CJ, Creasy SL, Matthews DD, Friedman MR, Stall RD. Characterizing the HIV care continuum and identifying barriers and facilitators to HIV diagnosis and viral suppression among black transgender women in the United States. *J Acquir Immune Defic Syndr*. 2018.
6. Cahn P, Madero JS, Arribas J, et al. Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) vs DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naïve adults with HIV-1 infection—Week 48 results from the GEMINI studies. Presented at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, Amsterdam, The Netherlands.
7. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. *Lancet* 2018. pii: S0140-6736(18)32462-0. doi:10.1016/S0140-6736(18)32462-0
8. CDC. HIV Among Women. <https://www.cdc.gov/hiv/group/gender/women/index.html>
9. Center KE, Gunn JK, Asaolu IO, Gibson SJ, Ehiri JE. Contraceptive use and uptake of HIV-testing among sub-Saharan African Women. *PLoS One*. 2016;11:e0154213.
10. Centers for Disease Control and Prevention (CDC). Achievements in public health. Reduction in perinatal transmission of HIV infection—United States, 1985-2005. *MMWR*. 2006;55(21):592-7.
11. Centers for Disease Control and Prevention (CDC). Diagnoses of HIV infection in the United States and dependent areas, 2017. HIV Surveillance Report. 2017;29:1-129. <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2017-vol-29.pdf>
12. Centers for Disease Control and Prevention. Vital signs: HIV prevention through care and treatment -- United States. *MMWR Morb Mortal Wkly Rep*. 2011;60:1618-1621.
13. Currier JS, Britto P, Hoffman RM, et al; 1077HS PROMISE Team. Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4  $\geq 400$  cells/mm<sup>3</sup>. *PLoS One*. 2017;12(5):e0176009.
14. De Jesus M, Carrete C, Maine C, Nalls P. Attitudes, perceptions and behaviours towards HIV testing among African-American and East African immigrant women in Washington, DC: implications for targeted HIV testing promotion and communication strategies. *Sex Transm Infect*. 2015;91(8):569-575.
15. Department of Health and Human Services (HHS) Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. <http://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0/>
16. DHSS. <https://aidsinfo.nih.gov/guidelines/html/3/perinatal/489/table-9--arv-drug-use-in-pregnant-hiv-infected-women>
17. EACS. EACS Guidelines Version 8.0. <http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelineshtml> 2015.

18. Elwell K. Facilitators and barriers to treatment adherence within PMTCT programs in Malawi. *AIDS Care*. 2016;28(8):971–975.
19. Farrow T, Deaton C, Nguyen N, et al. Cumulative safety review of elvitegravir and bicittegravir use during pregnancy and risk of neural tube defects. Presented at HIV Glasgow, 28-31 October 2018. Abstract P030.
20. FLAIR: Study to evaluate the efficacy, safety and tolerability of long-acting intramuscular cabotegravir and rilpivirine for maintenance of virologic suppression following switch from an integrase inhibitor in HIV-1 infected therapy naïve participants. <https://clinicaltrials.gov/ct2/show/NCT02938520?term=FLAIR&cond=HIV&rank=2>
21. Foster PP, Dalmida SG, McDougall GJ Jr. HIV knowledge, perceived risk and gender as modulators of salivary HIV rapid testing in African Americans. *HIV/AIDS Res Treat*. 2017;2017(Sep1):S31-s37.
22. Frye V, Wilton L, Hirshfeld S, et al. "Just because it's out there, people aren't going to use it." HIV self-testing among young, black MSM, and transgender women. *AIDS Patient Care STDS*. 2015;29(11):617-624. doi:10.1089/apc.2015.0100
23. Getter A, Sutton MY, Armon C, et al. Trends of racial and ethnic disparities in virologic suppression among women in the HIV Outpatient Study, USA, 2010-2015. *PLoS One*. 2018;13(1):e0189973.
24. Gilbert EM, Darin KM, Scarsi KK, McLaughlin MM. Antiretroviral pharmacokinetics in pregnant women. *Pharmacotherapy*. 2015 Sep 1;35(9):838-55.
25. Gruskin L, Gange SJ, Celentano D, et al. Incidence of violence against HIV-infected and uninfected women: findings from the HIV Epidemiology Research (HER) study. *J Urban Health*. 2002;79(4):512-524.
26. Gwadz M, Cleland CM, Kutnick A, et al. Factors associated with recent HIV testing among heterosexuals at high risk for HIV infection in New York City. *Front Public Health*. 2016;4:76.
27. Hoffman RM, Black V, Technau K, et al. Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. *J Acquir Immune Defic Syndr*. 2010;54(1):35-41.
28. <https://aidsinfo.nih.gov/guidelines/htmltables/3/5947>
29. <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2016-vol-28.pdf>
30. <https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/human-immunodeficiency-virus-hiv-infection-screening>
31. <https://www.viivhealthcare.com/media/press-releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivotal-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen.aspx>
32. Hubbard McCree D, Bradley E, Harris N. Changes in the disparity of HIV diagnosis rates among black women—United States, 2010–2014. *MMWR*. 2017;66(4):104-106.
33. Katirayi L, Namadingo H, Phiri M, et al. HIV-positive pregnant and postpartum women's perspectives about option B+ in Malawi: A qualitative study. *J Int AIDS Soc*. 2016;19(1):20919.
34. Kowalska J, Gökengin D, Aho I, et al. Exposure to dolutegravir in pregnant HIV-positive women in Central and Eastern Europe and neighbouring countries: data from the ECEE Network Group. HIV Glasgow. 28–31 October 2018. Glasgow, UK. Poster abstract P004.
35. Margolis D A et al. Safety, Efficacy and durability of long-acting CAB and RPV as two drug IM maintenance therapy for HIV-1 infection: LATTE-2 week 160 results. Presented at HIV Glasgow, 28-31 October, 2018.
36. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. *Lancet*. 2017;390(10101):1499-1510.
37. McDougall GJ Jr, Dalmida SG, Foster PP, Burrage J. Barriers and facilitators to HIV testing among women. *HIV/AIDS Res Treat*. 2016;2016(Sep1):S9-s13.
38. Messer LC, Quinlivan EB, Parnell H, et al. Barriers and facilitators to testing, treatment entry, and engagement in care by HIV-positive women of color. *AIDS Patient Care STDS*. 2013;27(7):398-407.
39. Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. *Lancet HIV*. 2018;5(5):e211-e220.
40. Momplaisir FM, Storm DS, Nkwihoreze H, Jayeola O, Jemmott JB. Improving postpartum retention in care for women living with HIV in the United States. *AIDS (London, England)*. 2018;32(2):133-142.
41. Money D, Lee T, O'Brien C, et al. An analysis of congenital anomalies in pregnant women living with HIV in Canada: no signal for neural tube defects in women exposed to dolutegravir. HIV Glasgow. 28–31 October 2018. Glasgow, UK. Poster abstract P001.
42. Nwangwu-Ike N, Frazier EL, Crepaz N, Tie Y, Sutton MY. Racial and ethnic differences in viral suppression among HIV-positive women in care. *JAIDS*. 2018;79(2):e56-e68.

43. Orkin C, Squires KE, Molina JM, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naïve adults with human immunodeficiency virus-1 infection: Week 48 results of the DRIVE-AHEAD trial. *Clin Infect Dis*. 2018.
44. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Available at <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>
45. Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. Downloaded Jan 4, 2019. (<http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf>)
46. Patel M, Tedaldi E, Armon C, et al. HIV RNA suppression during and after pregnancy among women in the HIV Outpatient Study, 1996 to 2015. *J Int Assoc Provid AIDS Care*. 2018 Jan 20;17:2325957417752259.
47. Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. *Lancet*. 2017;390:2073-2082.
48. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. *JAMA*. 2018;320(4):379-396
49. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. *PLoS One*. 2013;8(12):e81355.
50. Soon GG, Min M, Struble KA, et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). *AIDS Patient Care STDs*. 2012;26(8):444-453.
51. Squires K, Kityo C, Hodder S, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. *Lancet HIV*. 2016;3(9):e410-e420.
52. Swain CA, Smith LC, Nash D, et al. Postpartum loss to HIV care and HIV viral suppression among previously diagnosed HIV-infected women with a live birth in New York State. *PLoS One*. 2016;11(8):30160775.
53. Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial. *Clin Infect Dis*. 2018;66(11):1794-1797.
54. Treffry-Goatley A, Lessells R, Sykes P, et al. Understanding specific contexts of antiretroviral therapy adherence in rural South Africa: A thematic analysis of digital stories from a community with high HIV prevalence. *PLoS One*. 2016;11(2):e0148801.
55. United States Department of Health and Human Resources Panel on Antiretroviral Guidelines for Adults and Adolescents, Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV, and Panel on Treatment of Pregnant Women Living with HIV and Prevention of Perinatal Transmission. Recommendations Regarding the Use of Dolutegravir in Adults and Adolescents with HIV who are Pregnant or of Child-Bearing Potential, May 30, 2018. <https://aidsinfo.nih.gov/news/2109/recommendations-regarding-the-use-of-dolutegravir-in-adults-and-adolescents-with-hiv-who-are-pregnant-or-of-child-bearing-potential>
56. Weisman D, De Leuw P, Gute P, et al. Use of integrase inhibitors in HIV-positive pregnant women: data from the Frankfurt HIV Cohort. HIV Glasgow. 28-31 October 2018. Glasgow, UK. Poster abstract P002.
57. Zash R, Jacobson DL, Diseko M, et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. *Lancet Glob Health*. 2018;6(7):e804-e810. doi:10.1016/S2214-109X(18)30218-3
58. Zash R, Makhema J, Shapiro R. Neural-tube defects with dolutegravir treatment from the time of conception. *N Engl J Med*. 2018 Sep 6;379(10):979-981.
59. Zash R, Souda S, Chen JY, et al. Reassuring birth outcomes with tenofovir/emtricitabine/efavirenz used for prevention of mother to child transmission of HIV in Botswana. *J Acquir Immune Defic Syndr* (1999). 2016;71(4):428-436.